RU2010103105A - Пирензепин и его производные в качестве анти-амилоидных агентов - Google Patents
Пирензепин и его производные в качестве анти-амилоидных агентов Download PDFInfo
- Publication number
- RU2010103105A RU2010103105A RU2010103105/15A RU2010103105A RU2010103105A RU 2010103105 A RU2010103105 A RU 2010103105A RU 2010103105/15 A RU2010103105/15 A RU 2010103105/15A RU 2010103105 A RU2010103105 A RU 2010103105A RU 2010103105 A RU2010103105 A RU 2010103105A
- Authority
- RU
- Russia
- Prior art keywords
- halogen
- alkyl
- group
- compound
- amino group
- Prior art date
Links
- 229910052736 halogen Inorganic materials 0.000 claims abstract 125
- 125000003277 amino group Chemical group 0.000 claims abstract 50
- 150000001875 compounds Chemical class 0.000 claims abstract 50
- 150000002367 halogens Chemical group 0.000 claims abstract 34
- 125000004122 cyclic group Chemical group 0.000 claims abstract 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 22
- 239000001257 hydrogen Substances 0.000 claims abstract 22
- 125000005842 heteroatom Chemical group 0.000 claims abstract 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 229910052794 bromium Inorganic materials 0.000 claims abstract 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- -1 e.g. Inorganic materials 0.000 claims abstract 3
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 3
- 229910052740 iodine Inorganic materials 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 20
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 17
- 208000037259 Amyloid Plaque Diseases 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 12
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 9
- 230000015572 biosynthetic process Effects 0.000 claims 9
- 210000005013 brain tissue Anatomy 0.000 claims 9
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 206010002022 amyloidosis Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 6
- 230000003930 cognitive ability Effects 0.000 claims 5
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 4
- 229960003530 donepezil Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960003980 galantamine Drugs 0.000 claims 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 229960004136 rivastigmine Drugs 0.000 claims 4
- 229960001685 tacrine Drugs 0.000 claims 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 3
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 3
- 208000002177 Cataract Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000008021 deposition Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 102000013498 tau Proteins Human genes 0.000 claims 2
- 108010026424 tau Proteins Proteins 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 102000017927 CHRM1 Human genes 0.000 claims 1
- 101150073075 Chrm1 gene Proteins 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 235000008100 Ginkgo biloba Nutrition 0.000 claims 1
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 239000002439 beta secretase inhibitor Substances 0.000 claims 1
- 229940088623 biologically active substance Drugs 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- DKGJFKPIUSHDIT-UHFFFAOYSA-L disodium;propane-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCS([O-])(=O)=O DKGJFKPIUSHDIT-UHFFFAOYSA-L 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims 1
- 229960004135 idebenone Drugs 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims 1
- 229960002934 propentofylline Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229940045999 vitamin b 12 Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 abstract 1
- 101150113676 chr1 gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07111491 | 2007-07-02 | ||
| EP07111491.2 | 2007-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010103105A true RU2010103105A (ru) | 2011-08-10 |
Family
ID=40020257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010103105/15A RU2010103105A (ru) | 2007-07-02 | 2008-07-02 | Пирензепин и его производные в качестве анти-амилоидных агентов |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100247688A1 (enExample) |
| EP (1) | EP2173355A2 (enExample) |
| JP (1) | JP2010531854A (enExample) |
| KR (1) | KR20100038424A (enExample) |
| CN (1) | CN101778634A (enExample) |
| AU (1) | AU2008270247A1 (enExample) |
| BR (1) | BRPI0812849A2 (enExample) |
| CA (1) | CA2691844A1 (enExample) |
| IL (1) | IL202768A0 (enExample) |
| MX (1) | MX2009014126A (enExample) |
| NZ (1) | NZ582314A (enExample) |
| RU (1) | RU2010103105A (enExample) |
| WO (1) | WO2009004038A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| ES2693152T3 (es) * | 2011-05-10 | 2018-12-07 | Kyowa Hakko Kirin Co., Ltd. | Compuesto de pirimido-diazepinona |
| WO2013068592A1 (en) * | 2011-11-10 | 2013-05-16 | Fondation Jerome Lejeune | Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| CN116635034A (zh) * | 2020-09-22 | 2023-08-22 | K·E·克拉伦斯-史密斯 | 用于治疗人低胆碱能障碍的药物组合 |
| CA3192987A1 (en) * | 2020-09-22 | 2022-03-31 | Kathleen E. Clarence-Smith | Pharmaceutical combination for the treatment of human hypocholinergic disorders |
| WO2023137098A1 (en) * | 2022-01-16 | 2023-07-20 | Winsantor, Inc. | Compositions and methods for improving sexual sensory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| DE3818299A1 (de) * | 1988-05-30 | 1989-12-07 | Thomae Gmbh Dr K | Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4112014A1 (de) * | 1991-04-12 | 1992-10-15 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung |
| EP1781300A1 (en) * | 2004-07-16 | 2007-05-09 | ProteoSys AG | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| MX2008000461A (es) * | 2005-07-12 | 2008-03-10 | Abbott Gmbh & Co Kg | Compuestos de piridazina como inhibidores de la glucogeno sintasa cinasa 3. |
-
2008
- 2008-07-02 RU RU2010103105/15A patent/RU2010103105A/ru not_active Application Discontinuation
- 2008-07-02 KR KR1020107002421A patent/KR20100038424A/ko not_active Withdrawn
- 2008-07-02 EP EP08774661A patent/EP2173355A2/en not_active Withdrawn
- 2008-07-02 US US12/667,445 patent/US20100247688A1/en not_active Abandoned
- 2008-07-02 WO PCT/EP2008/058527 patent/WO2009004038A2/en not_active Ceased
- 2008-07-02 CN CN200880103247A patent/CN101778634A/zh active Pending
- 2008-07-02 CA CA002691844A patent/CA2691844A1/en not_active Abandoned
- 2008-07-02 MX MX2009014126A patent/MX2009014126A/es not_active Application Discontinuation
- 2008-07-02 AU AU2008270247A patent/AU2008270247A1/en not_active Abandoned
- 2008-07-02 BR BRPI0812849-9A2A patent/BRPI0812849A2/pt not_active IP Right Cessation
- 2008-07-02 JP JP2010513980A patent/JP2010531854A/ja not_active Withdrawn
- 2008-07-02 NZ NZ582314A patent/NZ582314A/en not_active IP Right Cessation
-
2009
- 2009-12-16 IL IL202768A patent/IL202768A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100247688A1 (en) | 2010-09-30 |
| JP2010531854A (ja) | 2010-09-30 |
| KR20100038424A (ko) | 2010-04-14 |
| WO2009004038A2 (en) | 2009-01-08 |
| BRPI0812849A2 (pt) | 2014-12-09 |
| IL202768A0 (en) | 2010-06-30 |
| AU2008270247A1 (en) | 2009-01-08 |
| NZ582314A (en) | 2012-04-27 |
| MX2009014126A (es) | 2010-03-29 |
| CA2691844A1 (en) | 2009-01-08 |
| WO2009004038A3 (en) | 2009-11-26 |
| AU2008270247A2 (en) | 2010-01-28 |
| EP2173355A2 (en) | 2010-04-14 |
| CN101778634A (zh) | 2010-07-14 |
| WO2009004038A8 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230218617A1 (en) | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid | |
| JP6766198B2 (ja) | 細胞生存率を向上させるための組成物およびその使用方法 | |
| US20200338097A1 (en) | Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions | |
| RU2012148713A (ru) | Новые соединения для лечения заболеваний, связанных с амилоидными или амилоидоподобными белками | |
| KR20100024951A (ko) | 세포를 자극하기 위한 방법 및 조성물 | |
| US10745429B2 (en) | Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| WO2009023299A9 (en) | Anti-angiogenic agents and methods of use | |
| WO2019221755A1 (en) | Piperlongumine analogues and uses thereof | |
| JP2010531854A5 (enExample) | ||
| JP2024510249A (ja) | 神経疾患を治療するための組成物およびその方法 | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| CA3101878A1 (en) | Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| NL2024431B1 (en) | Compounds for treatment of alzheimer’s disease | |
| KR20130103650A (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| JP2016523901A (ja) | モルホリン化合物またはピペラジン化合物、及びドネペジルを含む認知障害関連疾病の予防用または治療用の薬学的組成物 | |
| JP2010531854A (ja) | 抗アミロイド剤としてのピレンゼピンおよびその誘導体 | |
| ES2989515T3 (es) | Fármaco profiláctico o terapéutico para enfermedades neurodegenerativas | |
| JP6830895B2 (ja) | ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| JP2006516629A (ja) | 置換キノリンおよび置換ジフェニルスルホンを含有する組成物および方法 | |
| KR20140138640A (ko) | 비강내 졸피뎀 투여용 치료 조성물 | |
| WO2017035528A1 (en) | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | |
| US20210308138A1 (en) | Tissue transglutaminase modulators for medicinal use | |
| JP4505555B2 (ja) | 神経変性疾患治療剤 | |
| JP2019156798A (ja) | 多発性骨髄腫の治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20130930 |